Varenicline tartrate

CHF 72.00
In stock
SYN-3013-M0011 mgCHF 72.00
SYN-3013-M0055 mgCHF 108.00
SYN-3013-M01010 mgCHF 203.00
SYN-3013-M05050 mgCHF 646.00
SYN-3013-M100100 mgCHF 1'041.00
 
More Information
Product Details
Synonyms Chantix; Champix
Product Type Chemical
Properties
Formula C13H13N3 . C4H6O6
MW 211.3 . 150.1
CAS 375815-87-5
Purity Chemicals ≥95%
Appearance Solid.
Solubility Soluble in DMSO or ethanol.
Declaration Manufactured by SynKinase.
Other Product Data Target: Nicotinic ACh receptor | Kinase Group: N/A | Substrate: N/A

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.
InChi Key TWYFGYXQSYOKLK-CYUSMAIQSA-N
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF
Varenicline is a prescription medication used to treat smoking addiction. It is a partial agonist of the α4/β2 subtype of the nicotinic acetylcholine receptor. In addition, it acts on α3/β4 and weakly on α3β2 and α6-containing receptors. A full agonism was displayed on α7-receptors. It stimulates nicotine receptors weaker than nicotine and is similar to cytisine in this respect and different to the nicotinic antagonist bupropion. In vitro studies demonstrated that varenicline does not inhibit the cytochrome P450 enzymes (IC50 >6400 ng/mL): 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A4/5. In human hepatocytes in vitro, varenicline does not induce the cytochrome P450 enzymes 1A2 and 3A4.
Product References
  1. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation: J.W. Coe, et al.; J. Med. Chem. 48, 3474 (2005)
  2. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid: H. Rollema, et al.; Neuropharmacol. 52, 985 (2007)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.